|

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

RECRUITINGSponsored by University Hospital, Bordeaux
Actively Recruiting
SponsorUniversity Hospital, Bordeaux
Started2024-04-05
Est. completion2025-07
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06430424

Summary

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* age \> 18 years
* surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

Exclusion Criteria:

* systemic therapy received for non-glioblastoma tumor

Conditions3

CancerGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.